CHEST 2023 On Demand Pass-Key Revisions To GOLD 2023: What Are The Clinical Impacts?

Video Transcription

Video Summary

The video discusses the key revisions to the GOLD 2023 strategy for the management of chronic obstructive pulmonary disease (COPD). The video emphasizes the importance of making treatment decisions based on three factors: symptom burden, exacerbation risk, and blood eosinophil levels. The video highlights the removal of the previous Group C classification and its replacement with Group E, which includes patients with high exacerbation risk regardless of symptom burden. The initial therapy for Group E patients is recommended to be a combination of a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA). Triple therapy with an inhaled corticosteroid (ICS) is suggested only for patients with high blood eosinophil levels above 300. The video also stresses the importance of proper inhaler technique and the individual tailoring of inhaler selection based on patient factors such as cognitive function, manual dexterity, and peak inspiratory flow. The use of LABA-LAMA combination therapy is recommended as initial treatment for high symptom burden patients, while ICS-LABAs are no longer recommended as initial therapy in any patient group. The video concludes by highlighting the importance of non-pharmacologic approaches such as pulmonary rehabilitation and vaccination.

Meta Tag

Category Obstructive Lung Diseases

Session ID 1099

Speaker Sandra Adams

Speaker Nicola Hanania

Speaker Donald Mahler

Track Obstructive Lung Diseases

Keywords

GOLD 2023 strategy

COPD management

symptom burden

exacerbation risk

blood eosinophil levels

Group E classification

triple therapy

inhaler technique

pulmonary rehabilitation